Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1713-1723

  Treleaven, Christopher M ^a   Tamsett, Thomas J ^a   Bu, Jie ^a   Fidler, Jonathan A ^a   Sardi, S Pablo ^a   Hurlbut, Gregory D ^a   Woodworth, Lisa A ^a   Cheng, Seng H ^a   Passini, Marco A ^a   Shihabuddin, Lamya S ^a   Dodge, James C ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS ANTIBODY; BRAIN PROTEIN; CD3 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY BRAIN LEVEL; ANTIBODY TITER; ARTICLE; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE MARKER; DISEASE MODEL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NIEMANN PICK DISEASE; NONHUMAN; NORMAL HUMAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL GENETICS;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84867070624     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.114     Document Type: Article

References (49)

1. Bosch, A, Perret, E, Desmaris, N and Heard, JM (2000). Long-term and signifcant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 1: 63-70.
2. Cabrera-Salazar, MA, Roskelley, EM, Bu, J, Hodges, BL, Yew, N, Dodge, JC et al. (2007). Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther 15: 1782-1788. (Pubitemid 47434184)
3. Dodge, JC, Clarke, J, Song, A, Bu, J, Yang, W, Taksir, TV et al. (2005). Gene transfer of human acid sphingomyelinase corrects neuropathology and motor defcits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci USA 102: 17822-17827. (Pubitemid 41803581)
4. Dodge, JC, Haidet, AM, Yang, W, Passini, MA, Hester, M, Clarke, J et al. (2008). Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modifcation of aberrant glial cell activity. Mol Ther 16: 1056-1064. (Pubitemid 351737070)
5. Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
6. Kaspar, BK, Lladó, J, Sherkat, N, Rothstein, JD and Gage, FH (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-842. (Pubitemid 36962626)
7. Passini, MA, Bu, J, Roskelley, EM, Richards, AM, Sardi, S P, O'Riordan, CR et al. (2010). CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
8. Passini, MA, Dodge, JC, Bu, J, Yang, W, Zhao, Q, Sondhi, D et al. (2006). Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci 26: 1334-1342. (Pubitemid 43237004)
9. Chirmule, N, Propert, K, Magosin, S, Qian, Y, Qian, R and Wilson, J (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583. (Pubitemid 29465516)
10. Erles, K, Sebökovà, P and Schlehofer, JR (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59: 406-411. (Pubitemid 29468085)
11. Halbert, CL, Rutledge, EA, Allen, JM, Russell, DW and Miller, AD (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 74: 1524-1532. (Pubitemid 30044103)
12. Manning, WC, Zhou, S, Bland, M P, Escobedo, JA and Dwarki, V (1998). Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 9: 477-485. (Pubitemid 28149601)
13. Lowenstein, PR, Mandel, RJ, Xiong, WD, Kroeger, K and Castro, MG (2007). Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7: 347-360. (Pubitemid 47595777)
14. Christine, CW, Starr, PA, Larson, PS, Eberling, JL, Jagust, WJ, Hawkins, RA et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73: 1662-1669.
15. LeWitt, PA, Rezai, AR, Leehey, MA, Ojemann, SG, Flaherty, AW, Eskandar, EN et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10: 309-319.
16. McPhee, SW, Janson, CG, Li, C, Samulski, RJ, Camp, AS, Francis, J et al. (2006). Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8: 577-588. (Pubitemid 43827251)
17. Mandel, RJ (2010). CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 12: 240-247.
18. Worgall, S, Sondhi, D, Hackett, NR, Kosofsky, B, Kekatpure, MV, Neyzi, N et al. (2008). Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 19: 463-474. (Pubitemid 351748791)
19. Peden, CS, Burger, C, Muzyczka, N and Mandel, RJ (2004). Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78: 6344-6359. (Pubitemid 38715933)
20. Sanftner, LM, Suzuki, BM, Doroudchi, MM, Feng, L, McClelland, A, Forsayeth, JR et al. (2004). Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 9: 403-409. (Pubitemid 38404529)
21. Hurlbut, GD, Ziegler, RJ, Nietupski, JB, Foley, JW, Woodworth, LA, Meyers, E et al. (2010). Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther 18: 1983-1994.
22. Boutin, S, Monteilhet, V, Veron, P, Leborgne, C, Benveniste, O, Montus, MF et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.
23. Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J and Wilson, JM (2009). Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
24. Halbert, CL, Miller, AD, McNamara, S, Emerson, J, Gibson, RL, Ramsey, B et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fbrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440-447.
25. Barcia, C, Jimenez-Dalmaroni, M, Kroeger, KM, Puntel, M, Rapaport, AJ, Larocque, D et al. (2007). One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther 15: 2154-2163. (Pubitemid 350148932)
26. Passini, MA, Macauley, SL, Huff, MR, Taksir, TV, Bu, J, Wu, IH et al. (2005). AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther 11: 754-762. (Pubitemid 40567980)
27. Kaspar, BK, Erickson, D, Schaffer, D, Hinh, L, Gage, FH and Peterson, DA (2002). Targeted retrograde gene delivery for neuronal protection. Mol Ther 5: 50-56. (Pubitemid 34110480)
28. Grimm, D, Lee, JS, Wang, L, Desai, T, Akache, B, Storm, TA et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82: 5887-5911. (Pubitemid 351822263)
29. Scallan, CD, Jiang, H, Liu, T, Patarroyo-White, S, Sommer, JM, Zhou, S et al. (2006). Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107: 1810-1817. (Pubitemid 43289358)
30. Kreutzberg, GW (1996). Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318. (Pubitemid 26349059)
31. Mucke, L and Eddleston, M (1993). Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J 7: 1226-1232. (Pubitemid 23314357)
32. Akiyama, H, Barger, S, Barnum, S, Bradt, B, Bauer, J, Cole, GM et al. (2000). Infammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
33. Boillée, S, Vande Velde, C and Cleveland, DW (2006). ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52: 39-59. (Pubitemid 44466358)
34. Zlokovic, BV (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
35. Schuchman, EH and Desnick, RJ (2001). Niemann-Pick disease types A and B: acid sphingomyelinase defciencies. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). In the Metabolic and Molecular Basis of Inherited Disease, 8th edn. McGraw-Hill: New York. pp. 3589-3610.
36. Passini, MA, Bu, J, Fidler, JA, Ziegler, RJ, Foley, JW, Dodge, JC et al. (2007). Combination brain and systemic injections of AAV provide maximal functional and survival benefts in the Niemann-Pick mouse. Proc Natl Acad Sci USA 104: 9505-9510. (Pubitemid 47185809)
37. Skorupa, AF, Fisher, KJ, Wilson, JM, Parente, MK and Wolfe, JH (1999). Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 160: 17-27.
38. Dodge, JC, Treleaven, CM, Fidler, JA, Hester, M, Haidet, A, Handy, C et al. (2010). AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 18: 2075-2084.
39. Brockstedt, DG, Podsakoff, GM, Fong, L, Kurtzman, G, Mueller-Ruchholtz, W and Engleman, EG (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92: 67-75. (Pubitemid 29315987)
40. Wang, L, Cao, O, Swalm, B, Dobrzynski, E, Mingozzi, F and Herzog, RW (2005). Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 12: 1453-1464. (Pubitemid 41486134)
41. McMenamin, MM and Wood, MJ (2010). Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks. Gene Ther 17: 448-458.
42. Liu, G, Martins, I, Wemmie, JA, Chiorini, JA and Davidson, BL (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 25: 9321-9327. (Pubitemid 41464744)
43. Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). Preexisting AAV capsid-specifc CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792-800. (Pubitemid 46432000)
44. Hadaczek, P, Eberling, JL, Pivirotto, P, Bringas, J, Forsayeth, J and Bankiewicz, KS (2010). Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18: 1458-1461.
45. Markakis, EA, Vives, K P, Bober, J, Leichtle, S, Leranth, C, Beecham, J et al. (2010). Comparative transduction effciency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18: 588-593.
46. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specifcity. J Virol 76: 791-801. (Pubitemid 34033377)
47. Snyder, RO, Spratt, SK, Lagarde, C, Bohl, D, Kaspar, B, Sloan, B et al. (1997). Effcient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 8: 1891-1900. (Pubitemid 27499662)
48. Barbon, CM, Ziegler, RJ, Bercury, SD, Cherry, M, Li, C, Schuchman, E et al. (2004). Effcacy of AAV-mediated expression of acid sphingomyelinase at correcting the visceral and pulmonary manifestations of Niemann-Pick B disease. Mol Ther 9: S324. American Society for Gene Therapy: Minneapolis, MN.
49. Shihabuddin, LS, Numan, S, Huff, MR, Dodge, JC, Clarke, J, Macauley, SL et al. (2004). Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 24: 10642-10651. (Pubitemid 39557637)